# Iron Supplementation in TAVI and SAVR Patients With Iron Deficiency

Study · id `cardio:ct-nct04786769` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04786769](<https://clinicaltrials.gov/study/NCT04786769>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04786769

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2500 participants.

## Technical summary

Registry record NCT04786769. Randomized; quadruple masking; primary purpose treatment. Start 2022-01 (anticipated); primary completion 2025-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2500 participants (planned count; ClinicalTrials.gov record NCT04786769, source copy `cardio:ctgov-nct04786769-2021-03-08`, retrieved 2026-10-26)
- Planned start: 2022-01 (anticipated) (ClinicalTrials.gov record NCT04786769, source copy `cardio:ctgov-nct04786769-2021-03-08`, retrieved 2026-10-26)
- Primary completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT04786769, source copy `cardio:ctgov-nct04786769-2021-03-08`, retrieved 2026-10-26)
- Completion: 2025-06 (anticipated) (ClinicalTrials.gov record NCT04786769, source copy `cardio:ctgov-nct04786769-2021-03-08`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04786769-2021-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Iron Supplementation in TAVI and SAVR Patients With Iron Deficiency
- Acronym: INERTIA
- Condition: Aortic Stenosis
- Condition: Iron-deficiency
- Intervention (Drug): Ferric carboxymaltose
- Lead sponsor: Hospital de Santa Cruz, Portugal
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Ferric carboxymaltose (`core:ferric-carboxymaltose`)

## Provenance

Content hash: d18ca0f35b5be490706abc437846be6cde7614579109d27310d8d4a7722e7c8d
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
